[Comparative study of diflorasone diacetate and clobetasol-17-propionate in PUVA-resistant psoriasis].
In a double-blind controlled trial, we have compared the therapeutic effectiveness of Diflorason-Diacetate and Clobetasol-17-propionate with 50 PUVA-resistent psoriatics. Both externals resulted in a highly significant decline of psoriatic symptoms. The difference in therapeutic achievement between the two respective groups was statistically not significant. According to the physician's overall judgement, however, Clobetasol was favored significantly over Diflorasone-Diacetate, while the patients only showed a slight preference for Clobetasol. Based on these findings and previously published results, Diflorasone-Diacetate may be classified as one of the most effective skin corticosteroids, ranging just behind Clobetasol.
D001623:Betamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D002990:Clobetasol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004311:Double-Blind Method; D006801:Humans; D011701:PUVA Therapy; D010778:Photochemotherapy; D011565:Psoriasis / Q000188:drug therapy*
D001623:Betamethasone; D002990:Clobetasol; C014477:diflorasone
Vergleichsstudie mit Diflorasondiacetat und Clobetasol-17-Propionat bei PUVA-resistenter Psoriasis.